Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response

BACKGROUND: Sunitinib prolongs progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumours (pNET). Response Evaluation Criteria in Solid Tumors (RECIST)-defined partial responses (PR; classically defined as ⩾30% size decrease from baseline) are infrequent. METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamarca, Angela, Barriuso, Jorge, Kulke, Matthew, Borbath, Ivan, Lenz, Heinz-Josef, Raoul, Jean Luc, Meropol, Neal J, Lombard-Bohas, Catherine, Posey, James, Faivre, Sandrine, Raymond, Eric, Valle, Juan W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785750/
https://www.ncbi.nlm.nih.gov/pubmed/29161241
http://dx.doi.org/10.1038/bjc.2017.402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785750/
https://www.ncbi.nlm.nih.gov/pubmed/29161241
http://dx.doi.org/10.1038/bjc.2017.402

Ejemplares similares